Literature DB >> 19647480

Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.

Robert F Pass1.   

Abstract

A vaccine comprised of recombinant cytomegalovirus (CMV) envelope glycoprotein B (gB) with MF59 adjuvant developed in the 1990s recently was recently found to have efficacy for prevention of CMV infection in a phase 2 clinical trial in young mothers. This review briefly considers the rationale for gB as a vaccine antigen, the history of this CMV gB vaccine and the data supporting vaccine efficacy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19647480      PMCID： PMC2805195          DOI： 10.1016/j.jcv.2009.07.002

Source DB:  PubMed          Journal:  J Clin Virol        ISSN： 1386-6532            Impact factor:   3.168


  31 in total

1.  A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.

Authors:  R F Pass; A M Duliegè; S Boppana; R Sekulovich; S Percell; W Britt; R L Burke
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

Review 2.  Human cytomegalovirus glycoproteins.

Authors:  W J Britt; M Mach
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

3.  Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines.

Authors:  J B Wang; S P Adler; S Hempfling; R L Burke; A M Duliège; S E Starr; S A Plotkin
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

Review 4.  A recombinant subunit vaccine approach to HCMV vaccine development.

Authors:  R R Spaete
Journal:  Transplant Proc       Date:  1991-06       Impact factor: 1.066

5.  Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.

Authors:  D Navarro; E Lennette; S Tugizov; L Pereira
Journal:  J Med Virol       Date:  1997-08       Impact factor: 2.327

6.  Maternal immunity and prevention of congenital cytomegalovirus infection.

Authors:  Karen B Fowler; Sergio Stagno; Robert F Pass
Journal:  JAMA       Date:  2003-02-26       Impact factor: 56.272

7.  Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies.

Authors:  S Tugizov; D Navarro; P Paz; Y Wang; I Qadri; L Pereira
Journal:  Virology       Date:  1994-06       Impact factor: 3.616

8.  Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells.

Authors:  D Navarro; P Paz; S Tugizov; K Topp; J La Vail; L Pereira
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

9.  Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate.

Authors:  T Compton; D M Nowlin; N R Cooper
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

10.  Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

Authors:  S P Adler; S E Starr; S A Plotkin; S H Hempfling; J Buis; M L Manning; A M Best
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226
View more
  40 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010.

Authors:  Gisela Enders; Anja Daiminger; Lisa Lindemann; Frank Knotek; Ursula Bäder; Simone Exler; Martin Enders
Journal:  Med Microbiol Immunol       Date:  2012-03-08       Impact factor: 3.402

3.  Murine Cytomegalovirus Glycoprotein O Promotes Epithelial Cell Infection In Vivo.

Authors:  Joseph Yunis; Helen E Farrell; Kimberley Bruce; Clara Lawler; Orry Wyer; Nicholas Davis-Poynter; Ilija Brizić; Stipan Jonjić; Barbara Adler; Philip G Stevenson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

4.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

5.  Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.

Authors:  Flavia Chiuppesi; Teodora Kaltcheva; Zhuo Meng; Peter A Barry; Don J Diamond; Felix Wussow
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

Review 6.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 7.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

8.  Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.

Authors:  Ilona Baraniak; Florian Kern; Pavlo Holenya; Paul Griffiths; Matthew Reeves
Journal:  J Infect Dis       Date:  2019-06-19       Impact factor: 5.226

9.  Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.

Authors:  Flavia Chiuppesi; Felix Wussow; Erica Johnson; Chao Bian; Meng Zhuo; Augustine Rajakumar; Peter A Barry; William J Britt; Rana Chakraborty; Don J Diamond
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

10.  Requirements for guinea pig cytomegalovirus tropism and antibody neutralization on placental amniotic sac cells.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2020-02-18       Impact factor: 3.891
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.